Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cemiplimab

Boehringer Ingelheim headquarters

Boehringer plans new filings for Giotrif in lung cancer

Firm to file drug for squamous cell carcinoma of the lung

Gilead Sciences

Gilead files Complera follow-up with FDA

HIV therapy could be approved in the US by the end of this year

- PMLiVE

Opdivo approved via UK’s early drug access scheme

Bristol-Myers Squibb’s immunotherapy the first lung cancer drug approved by EAMS

Eli Lilly HQ

Lilly and Immunocore ink immunotherapy R&D deal

Firms will test new joint therapy in patients with melanoma

- PMLiVE

US expands recommended use of meningitis B vaccines

Butopts not to back routine use of GSK's Bexsero and Pfizer' Trumenba

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

- PMLiVE

Former Sanofi UK MD to head Teva UK

Steve Oldfield has been named as the firm’s new general manager

Teva Pharma logo

Teva set for FDA verdict on reslizumab early next year

Ruling for severe asthma therapy Cinquil expected by March 2016

- PMLiVE

Transparency debate extends to rejected drug applications

Claims from the BMJ made in new published study

- PMLiVE

GSK’s new asthma biologic gains FDA panel backing

British firm looking to help shore up its ageing respiratory portfolio 

- PMLiVE

Praluent and Repatha backed for approval in US

Sanofi and Amgen remain in fierce competition in PCSK9 inhibitors

- PMLiVE

Sanofi will resubmit Lyxumia for FDA approval in Q3

Follows the GLP-1 agonist's all-clear by ELIXA cardiovascular safety study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links